Similarly, low-dose IL-2 therapy, particularly in nanoparticle formulations, was shown to improve early-stage T1D by suppressing IL-23 expression and maintaining IL-25 levels, suggesting an immunoregulatory effect that may involve balancing effector and regulatory pathways [40]. The gene discussed is IL23A; the disease is type 1 diabetes mellitus.